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Abstract: Comprehensive modeling of the complex behavior of cellular networks during cellular reprogramming or during tumor 
metastasis, has become possible by integration of different biological scales into a multiscale model. Typically, these multiscale models 
combine probabilistic and deterministic aspects of cellular behavior. In this paper, a review is given of modeling studies of the group of 
NSCLC (non-small cell lung cancers), which has a rather amalgamative appearance. Due to the heterogenous genetic background and 
poor predictability of divergent pathological processes, the prognosis of NSCLC to date is still very poor. The role of two important 
phenotypic markers, namely the TTF1 (thyroid trancription factor 1) and EGFR (epidermal growth factor receptor), are discussed with 
respect to disease progression, migration and metastasis potential. A strategy for introducing the cell survival perspective in tumor 
expansion modeling is discussed in combination with visualization techniques based on cell-state modeling, similar to cell-state 
modeling in reprogramming studies. 
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1. Introduction 
During the first decade of this millennium, a few 
distinguishing discoveries have changed our 
understanding of cellular networks and of the 
behaviour of tumor cell populations. First, the Nobel 
prize winning discoveries of John Gurdon and Shinya 
Yamanaka demonstrated that mature cells can be 
reprogrammed to become pluripotent stem cells. 
Yamanaka showed that only four transcription factors 
were needed to generate all three germ layers of 
embryonal development [1, 2]. Then, new 
experimental evidence has been found establishing the 
role of stem cells in tumor development. Classically, 
chemotherapy has been founded on the paradigm of 
killing fast-growing tumor cells. In vitro studies now 
have ascertained that tumor cells have only limited 
proliferative potential, whereas another fraction of the 
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tumor cell population has stem-cell-like properties and 
gives rise to the majority of the tumor cell progeny [3]. 
Third, the finding that neoplastic development into 
metastasis may be explained in terms of an escape from 
homeostatic control following a cellular adaptive 
response to a stressful environment [4]. And finally, the 
microarray technology has profoundly changed the 
way of looking at biological data altogether. Therefore, 
not only NGS (Next-Generation Sequencing) 
techniques but a complete area of new analyis and 
interpretative tools became available and refurbished 
the research practice in this era. 
Comprehensive modeling of the growth of tumor 
systems has become possible following the 
understanding that different biological scales have to 
be integrated into a multiscale model. These biological 
scales, from initial molecular mechanisms at the 
transcription level until the functioning of vital organs 
during terminal disease phases, so far are only distantly 
related in varying disciplines. Most promising are 
mixed models integrating both probabilistic and 
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deterministic relations, between spatial (random) 
search mechanisms, dissemination routes (drainage 
systems), molecular dynamics and biochemical 
reaction pathways. 
Recent studies on reprogramming of sommatic cells 
into iPS (induced pluripotent stem) cells have 
addressed the dynamics of the process of cell 
reprogramming. Polo et al. [5] described a pattern of 
bivalent domains after a first transcriptional wave and 
identified genes that acted as “roadblocks” in 
reprogramming. Shu et al. [6] presented a complex 
“seesaw” model of lineage specification in 
reprogramming. The abstract notion of a cell-state 
landscape directing cell lineage development is 
discussed in a recent paper [7]. 
As Edelman [8] already pointed out, incorporating 
cellular differentiation mechanisms, as well as 
activation of apoptosis and random cell migration 
processes into one comprehensive model for cell 
(lineage) development is a tedious task. Cell lineage 
development is well documented in the myeloid and 
lymphoid pathways of normal and malignant 
hematopoiesis [9, 10]. Recent modeling is based on 
pathological examples which better help to understand 
the complex behavior of cellular networks. In this 
paper, we will focus on the behavior of NSCLC, which 
has still a very poor prognosis for long term survival. 
2. The NSCLC (non-small cell lung cancer) 
Case 
2.1 TTF1 Is Called a Proto-Oncogene in Lung Cancer 
To date, not a single marker is available to 
characterize all different phenotypes of NSCLC. A 
slight majority (approximately 55 %) of pulmonary 
adenocarcinomas expresses the TTF1 (thyroid 
transcription factor 1) [11]. Amplification of the TTF1 
gene is found in ~ 13 % of ACs (adenocarcinomas) and 
~ 9 % of SCCs (squamous cell carcinomas) [12]. 
On the other hand, TTF1 is expressed at early stages 
of thyroid, lung and brain development, and well 
before the expression of its target genes. This suggests 
a key role in the development of these organs. TTF1 is 
known as a member of the homeodomain-containing 
transcription factor family (reviewed by Boggaram 
[13]). In the thyroid, TTF1 controls the expression of 
the thyroglobulin [14], the thyrotropin receptor [15] 
and several other genes [13, 16]. In the brain, the 
important growth factor nestin appears to be regulated 
by TTF1, via the T1α promoter [17]. In the lung, 
however, TTF1 is essential for the expression of 
several members of the SP (surfactant protein) family 
(SP-A, SP-B, SP-C) [18-20], and regulates the 
expression of CCSP (Clara cell secretory protein) [21] 
and of the ABCA3 (ATP-binding cassette transporter 
A3) genes [22]. In the adult lung, TTF1 is expressed in 
the Type II epithelial (alveolar) cells and Clara 
bronchiolar epithelial cells (in bronchioles) [23] (Fig. 1).  
The finding that 2%-13% of lung adenocarcinomas 
show amplification of the TTF1 gene, suggests that 
over-expression of TTF1 target genes in one way or 
another stimulates malignant cell proliferation, 
although the relationship of these genes with cell cycle 
propagation is still elusive. TTF1 is called a 
proto-oncogene in lung cancer [13]. According to the 
escape-from-homeostatic-control-hypothesis of 
Nguyen [4], over-expression of the TTF1 gene and its 
target genes may also improve the conditions for 
metastasing cells to survive in a stressful environment.  
On the other hand, both ceramide, a product of 
sphingolipid breakdown, and RNAi (RNA-interference) 
molecules to TTF1 have blocking effects on cell cycle 
progression and increase apoptosis [13, 24, 25]. 
Ceramide is an important signaling molecule in the 
inflammatory response, for instance as a response to 
the release of mediators of acute lung injury (TNF-α, 
platelet-activating factor or Fas/Apo ligand) [24]. 
Ceramide decreases the release of SP-B, a hydrophobic 
protein which is essential for surfactant function and 
lung stability. The inhibitory effects of ceramide and 
RNAi appear to be exerted at the transcriptional level, 
via downregulation of TTF1 DNA binding activity [13, 
24].  
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Fig. 1A  Expression of TTF-1 and TTF-1-responsive genes in the lung (Boggaram 2009). Schematic drawing of lung and lung 
alveolus showing the locations of type I and type II cells and Clara epithelial cells. TTF-1 is expressed by alveolar type II and Clara 
epithelial cells. (© 2009, Biochemical Society, Clinical Science, Vol. 116, p. 28).   
 
 
Fig. 1B  Regulation of TTF-1 gene expression and of TTF-1-responsive genes (after Boggaram [13]).  
 
Finally, recent studies have shown that alveolar 
Type II cells have the capability of initiating lung 
tumor development [26] (see section 2.2 below). 
Moreover, AEC2s (alveolar Type II epithelial cells) 
were discovered to be stem cells of the adult lung [27]. 
2.2 Stem Cells of the Lung and Lung Tumor 
Development 
The role of slow-growing cancer stem cells in tumor 
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myeloid leukaemia by John E. Dick et al. [28]. 
According to this “cancer stem-cell hypothesis”, not all 
cancer cells are alike, and there exists a “pecking 
order” according to which an abnormal stem cell is 
both the key to forming and feeding a cancer. 
Nowadays, organ-typic stem cells have been 
discovered in many solid tissues, and the cancer stem 
cell hypothesis has been confirmed in vitro [3]. 
In the adult lung, these stem cell properties may be 
exerted by the SPC (surfactant associated protein 
C)-expressing alveolar Type II cells [26, 27]. In SPC+ 
alveolar cells, but not in SPC+ BASCs 
(bronchioalveolar stem cells) of the bronchioalveolar 
duct junction, activation of the KRAS-oncogene, alone 
or in combination with the removal of the tumor 
suppressor p53, resulted in development of alveolar 
tumors [26]. Also, using individual lineage-labeling, 
AEC2s were shown to self renew in vitro and 
differentiate over about a year in both AEC2s and cells 
expressing Type I markers , AEC1s (alveolar Type I 
epithelial cells) [27]. Moreover, after specific ablation 
of AEC2s, individual survivors undergo rapid clonal 
expansion and cell dispersal [27], proving the stem cell 
hypothesis for the lung alveoli. This at least 
corroborates the theory that NSCLC may be initiated in 
alveolar Type II cells [26]. 
2.3 EGFR Is an Intrinsic Mitogen, Causing a 
Migration Dominant Phenotype 
Another factor that is frequently overexpressed in 
NSCLC is the EGFR (epidermal growth factor 
receptor)[29, 30]. Binding to the extracellular domain 
of EGFR, for instance by EGF (epidermal growth 
factor) or TGFα (transforming growth factor α), 
produces several downstream effects that affect 
phenotypic cell behavior including proliferation, 
invasion, metastasis and inhibition of apoptosis [31]. A 
very prominent effect of these growth factors is that 
they lead to EGFR hyperactivity [32, 33], and thus 
increase tumor cell motility, invasiveness and finally 
enhance lung metastasis [34] (Fig. 2). Wang et al. [35] 
developed a multiscale model for investigating the 
tumor expansion dynamics of NSCLC within a 
two-dimensional microenvironment (in silico) (Fig. 3). 
They used the concentrations of EGF, glucose and the 
oxygen tension as external chemical cues. They found 
that a phase-transition from the proliferative to the 
migrative phenotype might occur, depending on the 
availability of the growth factor (EGF) and the distance 
to nutrient abundance. As a consequence, downstream 
EGFR-ERK (epidermal growth factor 
receptor-extracellular signal-regulated kinase) 
signaling (Fig. 2) may be processed more efficiently, 
resulting in an accelerated spatio-temporal expansion 
rate and increased metastasis [35]. 
2.4 Routes for Lung Cancer Metastasis 
In contrast to the enormous impact on cancer-related 
deaths, relatively few studies have addressed the 
possible routes for lung cancer metastasis [36]. 
In current pathology textbooks, the routes for cancer 
metastasis are classified into basically four main types, 
namely (1) contiguous invasion of adjacent tissues, (2) 
(retrograde) lymphatic dissemination, (3) vascular 
invasion and (4) metastasis via coelomic cavities (e.g. 
pleural dissemination). In the case of lung cancer, also 
retrograde venous seeding is possible, most notably via 
the paravertebral plexus. Most routes of cancer 
dissemination are characterized by some fortuitous, 
maximum likelihood principle. For instance, lymphatic 
vessels lack a basement mebrane, and therefore form 
an easy target for dissemination. The (para) vertebral 
venous plexuses, because of their valveless nature may 
allow unmitigated tumor cell dissemination [37]. This 
may explain how pelvic neoplasms, e.g., carcinoma of 
the prostate, may metastize in vertebral bodies: the 
tumor cells spread into the internal vertebral plexuses 
via their connections with the pelvic veins. This 
especially occurs when the blood flow is temporarily 
reversed by raised intra-abdominal pressure or postural 
alterations [38]. A similar route would be involved in 
metastases from breast, renal and lung cancers. 
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Fig. 2  Downstream signaling pathway triggered by epidermal growth factor receptor (EGFR)(modified after Wang et al. 
[35]). EGFR is an intrinsic mitogen, that in the presence of an extrinsic chemotactic stimulus (and depending on the cells location) may 
yield a migration-dominant cell phenotype. The cascade of phosphorylation leads to activation of the extracellular signal-regulated 
kinase (ERK-PP), resulting in a more effective signal processing in the migration-dominant phenotype (Wang et al. [35]).  
 
Fig. 3  Modeling of cell migration following a 2-D random walk lattice according to Wang et al. [35]. The migration decision of 
a cell in a  M x N lattice depends on an attractiveness formula: ijijij LT εψψ ).1(. −+= , with ψ the so-called ‘search precision 
parameter’ (for ψ = 0 , a random walk situation is found; for ψ = 1, the cell selects the location with the highest glucose concentration; 
ε is an error term following the normal distribution).  
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Whether the opportunistic behavior of disseminating 
tumor cells is the underlying cause for a lack of 
scientific interest or not, in multiscale stochastic 
modeling it plays an indisputable role [4] (see also 
section below).  
3. The Cell (Survival) Perspective 
Neither cell-free stochastic modeling, nor the theory 
of so-called cellular automata, so far have satisfactorily 
resolved the problem of multiscale cancer modeling, 
although in the case of NSCLC important progress has 
been made [35]. From the perspective of the abnormal 
cell, however, a number of pathways are identifiable, 
each of which influence and in combination they 
determine the cell survival rate. The cell survival 
perspective may therefore become a cornerstone     
for the next generation of multiscale cancer  
modeling. 
From the modeling viewpoint, difficulties arise from 
the versatility of cell groups during the process of 
malignant transformation. Practically, annotation 
systems may benefit from their correspondence with 
clinically obtained evidence. In this respect, 
pathological relevance is valued more importantly than 
mathematical elegance.  
Without going into detail too much, the probability 
for an abnormal cell to develop into a life-threatening 
cluster of metastases, may result from a number of cell 
events (cell division, tumor expansion, cell migration, 
etc.), each of which depending on the occurrence of a 
set of factors (genetic mismatch, DNA-methylation 
status, oxygen tension, glucose level, regulators of 
apoptosis, etc.). Formally, this Psurvival is a product of 
amplitudes P1i, P2j, ..Pmn  of m successive events at n 
locations, each of them depending on a different set of 
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The stochastic element of the model results from the 
vaste number of available cells and the capability of 
these cells to disseminate through the system via 
different (vascular) routes (see section 2.4). Another 
major observation from clinical practice is that the 
prevalence of cancer in the population increases with 
age. Therefore, in order to integrate the cell survival 
probabilities for an individual patient, the overall 
landscape of possible cell states and dissemination 
routes should reflect an age-dependent element.  
In this respect, the notion of DIP (density of 
information processing) allows for introducing a 
parameter for the interconnectedness of successive 
steps in a (neuronal or cellular) signaling network [39]. 
From this DIP, the notion of “trajectory density” was 
introduced [6]. (In section 4, we will comment on the 
notions of “trajectory density” and cell-state landscape 
for tumor development). 
For the overall survival prognosis, the rather 
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In this formula, the integration of the DIP parameter 
(according to age x of an individual and position i of the 
jth route in a cellular network with N nodes) causes the 
main challenge for making relevant predictions about 
an individuals prognosis. Also, an age- and 
network-dependent “fatality” ratio ϕ (x,i), reflecting 
the impact of (co)morbidity and life-threatening 
conditions on survival, does not result from   
modeling but is read from the experienced fact. As a 
result, Poverall tends to zero for lim t → ∞.       
Again, evidence from clinical practice will substantiate 
the (statistically relevant) developmental or 
pathological transformations in a living cell 
population. 
 






Fig. 4  Theoretical cell-state modeling in a 3-D hyperbody, depending on the cell proliferation/migration potential, a positional 
and age-dependent histiotypic index and local nematic-isotopic order parameters. Left (overall): Artist impression of a cell-state 
landscape. The histiotypic index represents an abstract age-dependence of the hyperbody on environmental (effects of high energy 
radiation on skin cells) or gross anatomical determinants (epi-, [neuro]endo- or mesodermal cues). The proliferation/migration potential 
is represented according to recent insights in cell-state modeling (reviewed in [7]). Right (detail): Interactions between migrating and 
resident cells may alter the nematic-isotopic order or cause transient local order parameters, influencing stochastic processes at a local 
scale.  
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4. Reprogramming and Cell-State Landscape 
The finding that mature cells can be reprogrammed 
to become pluripotent stem cells [1] echoed into new 
approaches for studying transformations of mature cell 
populations. In a recent paper [7], we discussed the 
abstract notions of defining roadmaps and/or 
roadblocks in reprogramming [5] and cell-state 
landscapes obtained from the analysis of density of 
trajectories [6]. Using a chosen 2D-projection of a 
hyperbody representing all possible cell-states, on a 
plane defined by two arbitrary axes and according to a 
third axis (e.g., pluripotency potential or cell survival 
potential), one may visualize the possible trajectories 
of a population of cells. Since cellular development in 
general does not follow a “linear pattern”, as pointed 
out by the “cancer stem-cell hypothesis” (see section 
2.2), more complex patterns may be discerned. For 
instance, visualization of “ridges”, “valleys” and 
“saddle-points” may indicate a barrier, a furrow or 
bifurcation point, according to which certain 
developmental pathways are blocked, guided, split or 
deviated. However, little is known about the 
fine-tuning of these processes, caused by local ordering 
parameters (that may be of nematic, isotopic or 
transient nature) (Fig. 4).  
Of course, the main challenge will be to integrate the 
experimental evidence obtained from developing 
immune cell networks or metastasing cell populations 
into similar cell-state landscapes. The conundrum of 
these hyperbody visualizations therefore relies on a 
reproducible, topographically relevant (histiotypically 
and with respect to local oderering) representation of 
these biochemical/molecular interaction data. The 
interaction of some known biochemical pathways and 
tumor development is well documented (e.g. 
Wnt-signaling in colon carcinoma [40]). To describe 
the proliferation-enhancing effect of R-spondin 
signalling on Lgr5+ stem cells and their association 
with Wnt-receptor activation, Clevers et al. used the 
metaphor of am amplifying relay system [41]. So the 
cancer stem-cell hypothesis may facilitate the 
introduction of new metaphors, and these metaphors 
are helpful in visualizing the cellular and molecular 
processes in an overall non-linear developmental 
pattern. Another interesting model system is found in 
the role of the BMPR1B gene (bone morphogenetic 
protein [BMP] receptor 1B) and epigenetical silencing 
due to an EZH2 (enhancer of Zeste 
homolog-2)-dependent mechanism. In this model, 
EZH2 seems to be involved in methylation of CpG 
islands in the BMPR1B promotor, causing initial 
glioblastoma development and brain tumorigenesis [42, 
43].  
In the case of NSCLC, studies on the prognostic and 
predictive uses of KRAS mutations and modification of 
EGFR signaling are promising [44]. The signaling 
network downstream of EGFR however is still elusive, 
containing several possible feedback loops that make 
the signaling network redundant and, therefore, 
difficult to read and tackle. Also the role of TTF1 gene 
products (see section 2.1) in differentiation of lung 
alveolar Type II cells remains unresolved. Moreover, 
so far no comprehensive map of all pathways involved 
in NSCLC has been drawn, let alone sufficient and 
effective therapies have been developed to cure or 
contain the disease.  
5. Conclusions 
Multiscale modeling in principle consists of 
combining biological data that are explained at two or 
more levels of compartmentalization. For instance, at 
the level of transcription and transcription regulation, 
at the level of cellular behavior (proliferation, 
migration…) or cellular phenotype, the pattern or route 
followed during metastasis, the development of 
secondary tumors and co-morbidity mechanisms. 
Some of these aspects of developmental or 
pathological transformation have been clarified 
according to deterministic studies (classically defined 
according to cause-and-effect relationships), others 
may be explained following probabilistic (or stochastic) 
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modeling. The latter aspects are locally recognized by 
random effects or by dynamical non-linear interactions 
at a larger distance. 
Although the group of NSCLC (non-small cell lung 
cancer) has a fragmentated appearance, due to genetic 
background and divergent pathological processes 
taking place, the disease became a target for multiscale 
modeling studies. In this paper, it is suggested that 
some visualization techniques used in cell-state 
modeling through reprogramming [1, 2, 5, 6] may 
become useful too in modeling tumor expansion and 
metastasis. However, more experimental studies and 
access to clinical data will be needed to integrate the 
different aspects of the disease into a comprehensive 
multiscale model. For instance, whether and how the 
over-expression (and/or amplification) of the TTF1 
gene in different adenocarcinomas is linked to cell 
cycle propagation. Another example is the well known 
relation between EGFR over-expression and increased 
metastasis; the interaction with other pathways in this 
multifaceted dragon, however, remains a challenge to 
multiscale modeling. 
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